We continuously develop and expand our robust pipeline to address patients' unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.

Please note that the medicines in the pipeline below are currently under clinical trial investigation and are not yet approved.

Pipeline Chart

* As of Oct 31, 2024

Pipeline Chart

5DXd ADCs

 (US/EU/Asia) HER2 low BC
Chemo naïve/post chemo
DESTINY-Breast08		 (US/EU/Asia) HER2+ NSCLC
(durvalumab, volrustomig and
rilvegostomig combo) 1L
DESTINY-Lung03		 (US/EU) BC, NSCLC
(pembrolizumab combo)
(JP/US) solid tumors
TROPION-PanTumor01		 (JP/US/EU/Asia) NSCLC (w/o AGA,
pembrolizumab combo)
TROPION-Lung02		 (JP/US/EU) NSCLC (w/o AGA,
durvalumab, rilvegostomig, volrustomig
and sabestomig combo) TROPION-Lung04
(JP/US/EU/Asia) NSCLC (JP/US/Asia) EGFR mutated NSCLC, 1/2L
(osimertinib combo)		  (JP/US)
renal cell carcinoma, ovarian cancer
(US/EU/Asia) TNBC
(US/EU/Asia) HER2+ BC 2L+/1L
DESTINY-Breast07		 (JP/US/EU/Asia) HER2 expressing GC
combo, 2L+/1L
DESTINY-Gastric03
 (US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(US/EU/Asia) solid tumors
(saruparib combo)
PETRA		 (CN) NSCLC, TNBC
TROPION-PanTumor02		 (US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(JP/US/EU/Asia) solid tumors
(saruparib combo)
PETRA		 (US/EU/Asia) in prep CRC, BTC, HCC 2L+
MK-1022-011		 (JP/US/EU/Asia) in prep StageIV NSCLC 1L
(pembrolizumab + carboplatin combo)
KEYMAKER-U01 Substudy 01A
(JP/US)
ESCC, CRPC, squamous NSCLC, SCLC, etc.
IDeate-PanTumor01		 (JP/US/EU/Asia)
ES-SCLC, 1L
IDeate-Lung03		  (JP/US/EU/Asia) in prep StageIV NSCLC 1L
(pembrolizumab ± carboplatin combo)
KEYMAKER-U01 Substudy 01A
(JP/US/EU/Asia)
HER2 expressing solid tumors
DESTINY-PanTumor02		 (CN) HER2 expressing solid tumors
DESTINY-PanTumor03		 (JP/US/EU/Asia) solid tumors
TROPION-PanTumor03
(JP/US/EU/Asia) EGFR mutated
NSCLC 2L (osimertinib combo)
ORCHARD		 (US/EU/Asia) resectable early-stage
NSCLC neoadjuvant (durvalumab combo)
NeoCOAST-2		 (JP/US/EU/Asia) ｓolid tumors
HERTHENA-PanTumor01
(JP/US/EU/Asia)
ES-SCLC 2L+
IDeate-Lung01		 (JP/US/EU/Asia)
solid tumors 2L+
IDeate-PanTumor02		  
(JP/US/EU/Asia) HER2+ BC
adjuvant*1
DESTINY-Breast05		 (JP/US/EU/Asia) HER2+ BC 1L
DESTINY-Breast09		 (JP/US/EU/Asia) HER2+ BC
neoadjuvant
DESTINY-Breast11
(JP/EU/Asia) HER2+ GC 2L
DESTINY-Gastric04		 (JP/US/EU/Asia) HER2 mutant NSCLC 1L
DESTINY-Lung04		 (JP/US/EU/Asia) in prep HER2 expressing
BTC 1L (mono or rilvegostomig combo)
DESTINY-BTC01
(JP/US/EU/Asia) non-squamous NSCLC (w/o AGA, PD-L1<50%) 1L (pembrolizumab combo)
TROPION-Lung07		 (JP/US/EU/Asia) NSCLC (w/o AGA, PD-L1≥50%) 1L (pembrolizumab combo)
TROPION-Lung08		 (JP/US/EU/Asia) non-squamous NSCLC (w/o AGA, PD-L1≥ 50%) 1L (rilvegostomig combo)
TROPION-Lung10
(JP/US/EU/Asia) Stage I adenocarcinoma
NSCLC adjuvant (rilvegostomig combo)
TROPION-Lung12		  (JP/US/EU/Asia) EGFR mutated NSCLC 1L (osimertinib combo)
TROPION-Lung14		 (JP/US/EU/Asia) EGFR mutated NSCLC 2L+ (mono or osimertinib combo)
TROPION-Lung15
(JP/US/EU/Asia) NSCLC (w/o AGA) 1L
(durvalumab combo)
AVANZAR		 (JP/US/EU/Asia) TNBC (PD-1/PD-L1 inhibitor ineligible) 1L
TROPION-Breast02		 (JP/US/EU/Asia) TNBC adjuvant※1 (mono or durvalumab combo)
TROPION-Breast03
(JP/US/EU/Asia) TNBC neoadjuvant and adjuvant (durvalumab combo)
TROPION-Breast04		 (JP/US/EU/Asia) PD-L1 positive TNBC 1L (mono or durvalumab combo)
TROPION-Breast05		 (JP/US/EU/Asia) EGFR mutated NSCLC 2L
HERTHENA-Lung02
(JP/US/EU/Asia)
ES-SCLC 2L
IDeate-Lung02
    
(JP/US/EU) HR+ and HER2 low or HER2 ultralow BC chemo naïve
DESTINY-Breast06		 (US/EU) non-squamous NSCLC 2L+
TROPION-Lung01		 (JP/US/EU/CN) HR+ and HER2 low or HER2 negative BC 2/3L
TROPION-Breast01
(US) EGFR mutated
NSCLC 3L
HERTHENA-Lung01		  

：Orphan drug designation (designated in at least one country/region among JP, US
：Breakthrough Designation (US)
□：Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of Phase2 trials
※1 Adjuvant therapy for patients with residual invasive disease following neoadjuvant therapy
AGA: actionable genomic alterations, BTC: biliary tract cancer, BC: breast cancer, ES-SCLC: extensive stage-small cell lung cancer, GC: gastric cancer, HR: hormone receptor, NSCLC: non-small cell lung cancer, TNBC: triple negative breast cancer

Next Wave

■Oncology ■Specialty Medicine ■Vaccine

DS-1055 (JP/US)
Anti-GARP antibody
Solid tumors		 DS-9606 (US/EU)
CLDN6-directed ADC
Solid tumors		 DS-1103
Anti-SIRPα antibody
HER2 expressing or mutant solid tumors, HER2 low BC (ENHERTU® combo)
DS-1471
Anti-CD147 antibody
Solid tumors		 Valemetostat EZH1/2 inhibitor,
HER2+ GC, HER2 low BC (ENHERTU® combo) and non-squamous NSCLC (Dato-DXd combo)		  
DS-3939
TA-MUC1-directed ADC
Solid tumors		 MK-6070 (DS3280) (US)
DLL3 directed tri-specific T-cell engager
DLL3 expressing advanced cancer		 DS-7011 (JP/US/EU/Asia)
Anti-TLR7 antibody
Systemic lupus erythematosus
DS-2325 (EU)
KLK5 inhibitor
Netherton syndrome
  
Valemetostat (EU)
EZH1/2 inhibitor
BCL		 DS-1001 (JP)
Mutant IDH1 inhibitor
Glioma		 DS-1211 (US/EU)
TNAP inhibitor
Pseudoxanthoma elasticum
Pexidartinib (JP/Asia)
CSF-1/KIT/FLT3 inhibitor
Tenosynovial giant cell tumor		 Esaxerenone (JP)
MR blocker
Diabetic nephropathy		  
DS-5670 (JP)
COVID-19 mRNA vaccine (mutant strain), COVID-19
(booster vaccination, 5 to 11 aged children)		 VN-0102/JVC-001 (JP)
Mixed measles-mumps-rubella vaccine

：Orphan drug designation (designated in at least one country/region among JP, US and EU)
：Fast Track Designation (US)
：Rare Pediatric Disease Designation (US)
BC: breast cancer, BCL: B cell lymphoma, GC: gastric cancer, NSCLC: non-small cell lung cancer